<DOC>
	<DOCNO>NCT00005803</DOCNO>
	<brief_summary>This phase I/II trial study well autologous stem cell transplant follow donor stem cell transplant work treat patient lymphoma return respond treatment . Peripheral blood stem cell transplant use stem cell patient donor may able replace immune cell destroy chemotherapy use kill cancer cell . The donated stem cell may also help destroy remain cancer cell ( graft-versus-tumor effect ) .</brief_summary>
	<brief_title>Autologous Stem Cell Transplant Followed Donor Stem Cell Transplant Treating Patients With Relapsed Refractory Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate engraftment human leukocyte antibody ( HLA ) identical peripheral blood stem cell ( PBSC ) allografts give condition total-body irradiation ( TBI ) ( 200cGy ) +/- fludarabine ( fludarabine phosphate ) , 90 mg/m^2 post-grafting immunosuppression cyclosporine ( CSP ) /mycophenolate mofetil ( MMF ) refractory relapse lymphoma patient follow initial autologous peripheral blood stem cell transplant ( PBSCT ) disease cytoreduction . II . To determine non-relapse mortality day 100 post-non-myeloablative allografting follow mobilization high-dose chemotherapy autografting . SECONDARY OBJECTIVES : I . To determine disease free survival overall survival non-myeloablative allografting follow autologous PBSCT . OUTLINE : CONDITIONING REGIMEN : Patients match , related stem cell donor receive cyclophosphamide intravenously ( IV ) day -6 -5 undergo TBI twice daily ( BID ) day -3 -1 . Patients match , unrelated stem cell donor receive carmustine IV 3 hour day -7 , etoposide IV 2 hour BID day -6 -3 , cytarabine IV 3 hour BID day -6 -3 , melphalan IV 30 minute day -2 . TRANSPLANTATION : All patient undergo autologous PBSCT day 0 . NON-MYELOABLATIVE CONDITIONING : Beginning 40-120 day follow PBSC transplant , patient related donor undergo TBI day 0 . Patients unrelated donor receive fludarabine phosphate IV 30 minute day -4 -2 undergo TBI day 0 . TRANSPLANTATION : Patients undergo non-myeloablative allogeneic PBSCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) BID day -3 56 ( patient relate donor ) 100 ( patient unrelated donor ) follow taper day 180 . Patients also receive mycophenolate mofetil PO BID day 0-27 ( patient relate donor ) thrice daily ( TID ) day 0-27 , BID day 28-40 followed taper day 96 ( patient unrelated donor ) . Some patient may undergo donor lymphocyte infusion evidence disease progression evidence graft-vs-host disease ( GVHD ) . After completion study treatment , patient follow day 180 , 1 year , 1.5 year , 2 year , 3 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<criteria>Patients lymphoma ( nonHodgkin lymphoma [ NHL ] , chronic lymphocytic leukemia/small lymphocytic lymphoma [ CLL/SLL ] Hodgkin 's lymphoma ) primary refractory relapse disease standard chemotherapy high risk relapse conventional autografting ; patient diagnosis CLL ( small lymphocytic lymphoma ) diagnosis CLL progress prolymphocytic leukemia ( PLL ) , Tcell CLL PLL Must HLA genotypically phenotypically identical related donor , minimum , high likelihood identify HLAmatched unrelated donor ; determination availability suitable unrelated donor may base WorldBook search Crossover tandem autologousallogeneic research protocol ( # 2241 ) allow patient loses suitable HLAmatched relate unrelated donor available HLAhaploidentical donor receive allogeneic transplantation patient meet eligibility criterion subsequent study Crossover tandem autologousallogeneic research protocol ( # 2241 ) allow suitable HLAmatched relate unrelated donor identify receive allogeneic transplantation patient meet eligibility criterion subsequent study Signed informed consent Detectable tumor radiographic study bone marrow biopsy prior mobilization regimen Expected survival &gt; = 3 month study entry DONOR : HLA genotypically phenotypically identical relate donor DONOR : Must consent granulocytecolony stimulate factor ( GCSF ) ( filgrastim ) administration leukapheresis PBSC allograft subsequent donor lymphocyte infusion ( DLI ) DONOR : Must adequate vein leukapheresis agree placement central venous catheter ( femoral subclavian ) DONOR : Age &lt; 75 year ( yr ) , old donor may consider review Patient Care Conference DONOR : Fred Hutchinson Cancer Research Center ( FHCRC ) matching allow grade 1.0 2.1 ; unrelated donor prospectively : match HLAA , B , C , DRB1 DQB1 high resolution typing ; single allele disparity allow HLAA , B , C define high resolution type DONOR : Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive antidonor cytotoxic crossmatch absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow DONOR : Only GCSF mobilize peripheral blood mononuclear cell ( PBMC ) permit hematopoietic stem cell ( HSC ) source protocol Life expectancy severely limited disease lymphoma Prior autologous hematopoietic stem cell transplant Patients high risk venoocclusive disease liver ( criteria yet rigorously define include bilirubin &gt; 2.0 mg serum glutamic oxaloacetic transaminase [ SGOT ] serum glutamate pyruvate transaminase [ SGPT ] &gt; 2 x normal ) ; patient may accept outside range clear gastrointestinal ( GI ) consult Cardiac ejection fraction ( EF ) &lt; 40 % multigated acquisition ( MUGA ) scan cardiac echocardiogram ( echo ) ( unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; patient active history cardiac disease evaluate appropriate cardiac study and/or consult ; ejection fraction require age &gt; 50 year history anthracyclines history cardiac disease ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Baseline serumcreatinine &gt; 2.0 mg/dl calculate measured creatinine clearance &lt; 50 ml/minute Seropositive human immunodeficiency virus ( HIV ) Pulmonary dysfunction measure correct diffusing capacity lung carbon monoxide ( DLCO ) &lt; 50 % predict total lung capacity ( TLC ) &lt; 30 % , forced expiratory volume 1 second ( FEV1 ) &lt; 30 % and/or receive supplementary continuous oxygen ; FHCRC principal investigator ( PI ) study must approve enrollment patient pulmonary nodule Pregnancy breastfeed Patients poorly control hypertension despite hypertensive medication Karnofsky score le 60 ; pediatric criterion : Lansky PlayPerformance Score &lt; 40 Patients cluster differentiation ( CD ) 34 select auto graft Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) ; exclusion apply patient nonhematologic malignancy require therapy Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence ; exclusion apply patient nonhematologic malignancy require therapy DONOR : Identical twin DONOR : Age le 12 year DONOR : Pregnancy DONOR : Human immunodeficiency virus ( HIV ) seropositivity DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet FHCRC criterion stem cell donation DONOR : Donor ( center ) exclusively donate marrow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>